Vertex Pharmaceuticals

March 9, 2017March 9, 2017

Vertex Acquires Potential CF Therapy, CTP-656, a Deuterium-Modified Form of Kalydeco

Cystic Fibrosis, News

Vertex Pharmaceuticals has signed a $160 million purchase agreement to acquire CTP-656, a potential treatment for cystic fibrosis (CF), from Concert Pharmaceuticals. The agreement covers development and marketing rights worldwide. ... Read more

June 16, 2016June 16, 2016

Promising Results of Kalydeco and Orkambi for Cystic Fibrosis Presented at European CF Conference

News

Vertex Pharmaceuticals scientists presented positive results from clinical studies evaluating Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor) at the 39th European Cystic Fibrosis Society (ECFS) Conference June 8-11 in Basel, Switzerland. The presentations included real-world data from ... Read more

November 19, 2015

Vertex’s Cystic Fibrosis Therapy Expands to Younger Children, More Adults

Cystic Fibrosis, News

Vertex Pharmaceuticals Inc. recently confirmed that the European Commission has expanded the indication of Kalydeco® (ivacaftor) to two more groups of patients: children ages 2 to 5 with cystic fibrosis (CF) who have at least ... Read more

October 27, 2015November 5, 2015

Vertex and CRISPR Therapeutics Partner to Advance Gene Therapies for Cystic Fibrosis, Sickle Cell

Cystic Fibrosis, News

Vertex Pharmaceuticals, Inc., and CRISPR Therapeutics announced a new strategic research partnership focused on utilizing the CRISPR-Cas9 gene editing platform in the potential discovery and development of new gene therapies. The companies plan to focus ... Read more

October 12, 2015November 5, 2015

Vertex Presents Key Findings on Kalydeco, Orkambi & Experimental CF Therapies at NACFC

Cystic Fibrosis, News

A series of new updates and future development plans were recently announced by Vertex regarding its approved and candidate drugs to treat Cystic fibrosis (CF). The announcements, made at the 29th Annual ... Read more

June 12, 2015November 5, 2015

Vertex Presents Data at European Cystic Fibrosis Society (ECFS) Conference on Orkambi Combo Therapy

Cystic Fibrosis, News

Vertex Pharmaceuticals recently announced results from its PROGRESS long-term extension trial that is evaluating the efficacy of the ORKAMBI (lumacaftor/ivacaftor) investigational regimen in patients with cystic fibrosis (CF). Cystic Fibrosis patients aged ... Read more

May 13, 2015November 5, 2015

Vertex’s New CF Drug Combo Receives Positive FDA Recommendation

Cystic Fibrosis, News

The U.S. Food and Drug Administration (FDA) has issued a positive evaluation of ORKAMBI (lumacaftor/ivacaftor) as a recommended treatment for cystic fibrosis (CF) patients 12 years and older with two copies of the F508del mutation ... Read more

March 27, 2015November 5, 2015

Vertex Shares Slide After Combined Cystic Fibrosis Therapy Disappoints in Preliminary Data

Cystic Fibrosis, News

Shares of Vertex Pharmaceuticals Inc. fell sharply in the wake of disappointing results of the company’s drug combination of experimental drug VX-661 with FDA-approved Kalydeco. The company stated that its investigational cystic fibrosis drug combination drug did ... Read more

December 30, 2014November 5, 2015

FDA Approves Kalydeco for Cystic Fibrosis Patients with R117H Mutation

Cystic Fibrosis, News

The U.S. Food and Drug Administration (FDA) has approved the prescription of Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF) patients 6 years and older with the R117H mutation in the ... Read more

November 25, 2014November 25, 2014

Cystic Fibrosis Foundation Sells Vertex Royalty Rights for $3.3 Billion

News

The Cystic Fibrosis Foundation recently announced its not-for-profit branch, Cystic Fibrosis Foundation Therapeutics, has signed a strategic transfer of owned Vertex Pharmaceuticals royalty rights to Royalty Pharma for $3.3 billion. ... Read more